GREGORY WINTER

Sir Gregory Winter stands as a towering figure in both scientific discovery and venture capital, serving as a co-founder and Partner at Ahren Innovation Capital. A recipient of the 2018 Nobel Prize in Chemistry, his unparalleled expertise in molecular biology and biotechnology forms the bedrock of Ahren's investment strategy, which targets transformative deep technology and life science companies. His journey from groundbreaking researcher to influential investor exemplifies a unique blend of scientific rigor and entrepreneurial vision.

At Ahren Innovation Capital, Sir Gregory plays a pivotal role in identifying and nurturing ventures poised to revolutionize industries. Ahren is renowned for its focus on "deep tech," investing in companies that leverage fundamental scientific breakthroughs across sectors such as life sciences, artificial intelligence, and advanced engineering. Sir Gregory's deep understanding of these complex fields allows Ahren to back "science entrepreneurs" who are developing solutions to some of the world's most pressing challenges, from novel therapeutics to sustainable technologies. His involvement ensures that Ahren's portfolio companies are built on robust scientific principles and possess genuine disruptive potential.

Sir Gregory's illustrious career began with pioneering research at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge, UK. It was here that he developed the revolutionary technique of phage display, a method for evolving new proteins and antibodies. This work laid the foundation for the development of numerous therapeutic antibodies, including Humira, one of the world's best-selling drugs. His scientific contributions have directly led to the creation of life-saving medicines for conditions ranging from autoimmune diseases to cancer.

Beyond his academic achievements, Sir Gregory has a remarkable track record as a biotech entrepreneur. He founded Cambridge Antibody Technology (CAT), which developed the first fully human therapeutic antibody and was later acquired by AstraZeneca. He also co-founded Domantis, a company focused on novel antibody fragments, which was acquired by GlaxoSmithKline, and Bicycle Therapeutics, a clinical-stage biotechnology company. These ventures underscore his ability to translate scientific innovation into successful commercial enterprises, a skill he now brings to Ahren's portfolio companies.

His knighthood in 2004 for services to molecular biology and his tenure as Master of Trinity College, Cambridge, further highlight his significant contributions to both science and academia. At Ahren, Sir Gregory Winter continues to shape the future by investing in the next generation of scientific pioneers, ensuring that groundbreaking research finds the capital and guidance needed to make a real-world impact. His unique perspective, combining Nobel-level scientific insight with proven entrepreneurial success, makes him a formidable force in the global venture capital landscape, driving innovation that promises to benefit humanity.